

RELAPSED/REFRACTORY FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIAS (AML)

HALL 5
TOLEDO AUDITORIUM
BARCELONA, SPAIN

Chair
Jorge Cortes, USA

This educational activity is provided by ESMO
and supported by Daiichi Sankyo Europe GmbH.



SUNDAY, 29 SEPTEMBER 2019
18:30 – 20:00

18:30 Introduction
Jorge Cortes, Augusta, GA, USA

18:35 Molecular profiling, prognosis and present guidelines
for Relapsed/Refractory AML
Lars Bullinger, Ulm, Germany

18:55 Are FLT3 Mutated AML a special entity?
Gert Ossenkoppele, Amsterdam, Netherlands

19:15 Recent results with FLT3 Inhibitors in FLT3-ITD
positive Relapsed/Refractory AML and future
development
Jorge Cortes, Augusta, GA, USA

19:45 Questions/Answers from the audience to panelists
Lars Bullinger, Ulm, Germany;
Gert Ossenkoppele, Amsterdam, Netherlands;
Jorge Cortes, Augusta, GA, USA

19:55 Conclusion
Jorge Cortes, Augusta, GA, USA

